Roche has installed “stronger gates” to ensure that drug candidates only make it into phase 3 trials if they have a high likelihood of success, CEO Thomas Schinecker has revealed. Pointing to a slump ...
aTyr Pharma is a small-cap biotech focused on Efzofitimod for interstitial lung disease (ILD), a group of lung-scarring diseases. In 2021, the company completed a phase 1b/2a trial in pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results